CNTGFCentogene N.V.

About Centogene N.V. (CNTGF)

Centogene N.V. (CNTGF) is a Diagnostics & Research company headquartered in Rostock, Germany whose shares trade over-the-counter on the OTCQB tier.

CENTOGENE's mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank - providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Products and services

Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 850,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 300 peer-reviewed publications. By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases.

CNTGF key facts

Ticker symbol

CNTGF

Market tier

OTCQB

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Rostock, Germany

Country of incorporation

NL

Year of incorporation

2018

Employees

493

Estimated market cap

$4.36M (as of Apr 15, 2025)

Shares outstanding

29,817,079

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Centogene N.V. leadership

• Kim Stratton — CEO
• Peter Bauer — Chief Med. Officer
• Lennart Streibel — IR
• Jan Boysen — Legal Asst.

Explore more: Diagnostics & Research stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with C